{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,11,10]],"date-time":"2022-11-10T07:26:32Z","timestamp":1668065192771},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"02","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aktuelle Urol"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Zusammenfassung<\/jats:title><jats:p>Aufgrund der eingeschr\u00e4nkten Wirksamkeit der passiven Applikationsweise von BCG und\n      Mitomycin-C (MMC) und in den letzten Jahren bestehenden BCG-Lieferengp\u00e4ssen ist eine\n      Verbesserung der onkologischen Ergebnisse der adjuvanten Instillationstherapie beim\n      nicht muskelinvasiven Harnblasenkarzinom (NMIBC) durch Entwicklung neuartiger\n      Instillationsubstanzen und Applikationsweisen erforderlich.<\/jats:p><jats:p>Gemcitabin ist als generisch verf\u00fcgbare Substanz in zahlreichen randomisierten Studien in\n      den verschiedenen Risikokonstellationen untersucht worden und zeigt insbesondere im\n      BCG-unresponsiven Stadium ein verbessertes rezidivfreies \u00dcberleben im Vergleich zur\n      BCG-Rechallenge und MMC. Eine neuartige Instillationsform stellt das\n      Gemcitabin-intravesical-releasing system (GemRIS) dar, welches in der Kombination mit dem\n      systemisch wirksamen Checkpointinhibitor Cetrelimab in derzeit anlaufenden klinischen Studien\n      getestet wird. Hyperthermes intravesikales MMC (HIVEC), welches extrakorporal erw\u00e4rmt und in\n      die Blase zirkuliert, f\u00fchrt zu einer Konzentrationssteigerung von MMC in der Blasenwand und\n      wird im Rahmen klinischer Studie bereits getestet. Nadofaragene firadenovec (rAd-IFN-\u03b1\/Syn3)\n      ist ein rekombinantes Adenovirus zur Steigerung der Interferon-alpha-Konzentration im Urothel\n      und bietet erstmalig die M\u00f6glichkeit eine intravesikale Gentherapie f\u00fcr die urologischen\n      Praxis zu etablieren. Daten aus einer aktuellen Phase-III Studie legen im BCG-unresponsiven\n      Stadium eine h\u00f6here Wirksamkeit bei g\u00fcnstigerem Nebenwirkungsprofil im Vergleich zu Studien\n      mit einer PD-(L)1-Monotherapie nahe. Opportuzumab monatox ist ein rekombinantes\n      Fusionsprotein, welche nach EpCAM-Binding zu einer Freisetzung von Pseudomonas aeruginosa\n      Exotoxin f\u00fchrt, welches hiernach einen zytotoxischen Zellschaden einleitet. N-803 ist ein\n      Interleukin (IL)-15 Superagonist, welcher im Kombination mit BCG in einer Phase Ib Studie ein\n      dauerhaftes komplettes Ansprechen \u00fcber 72 Monate bei 9 intermediate\/high-risk Patienten\n      zeigte und bereits 2019 eine Vorabzulassung durch die FDA erhalten hat.<\/jats:p>","DOI":"10.1055\/a-1677-0952","type":"journal-article","created":{"date-parts":[[2022,2,16]],"date-time":"2022-02-16T23:47:03Z","timestamp":1645055223000},"page":"148-152","source":"Crossref","is-referenced-by-count":1,"title":["Adjuvante Instillationstherapie des nicht muskelinvasiven Harnblasenkarzinoms \u2013 neue Optionen abseits von BCG und Mitomycin"],"prefix":"10.1055","volume":"53","author":[{"given":"Georgios","family":"Gakis","sequence":"additional","affiliation":[{"name":"Department of Urology and Pediatric Urology, University Hospital of W\u00fcrzburg, W\u00fcrzburg, Germany"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2022,2,16]]},"reference":[{"key":"ref2","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1007\/s00120-020-01233-6","article-title":"Immuno-oncological therapeutic options in high-risk non-muscle invasive bladder cancer","volume":"59","author":"MW Kramer","year":"2020","journal-title":"Urologe A"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.eururo.2019.09.035","article-title":"EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort(dagger): Under the Auspices of the EAU-ESMO Guidelines Committees","volume":"77","author":"JA Witjes","year":"2020","journal-title":"Eur Urol"},{"key":"ref4","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.eururo.2012.08.009","article-title":"ICUD-EAU International Consultation on Bladder Cancer 2012: Radical cystectomy and bladder preservation for muscle-invasive urothelial carcinoma of the bladder","volume":"63","author":"G Gakis","year":"2013","journal-title":"Eur Urol"},{"key":"ref5","doi-asserted-by":"publisher","first-page":"CD009294","DOI":"10.1002\/14651858.CD009294.pub2","article-title":"Intravesical gemcitabine for non-muscle invasive bladder cancer","volume":"1","author":"G Jones","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"key":"ref6","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1111\/j.1464-410X.2011.10880.x","article-title":"Intravesical gemcitabine therapy for non-muscle invasive bladder cancer (NMIBC): a systematic review","volume":"109","author":"MD Shelley","year":"2012","journal-title":"BJU Int"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1016\/j.eururo.2009.06.010","article-title":"Single postoperative instillation of gemcitabine in patients with non-muscle-invasive transitional cell carcinoma of the bladder: a randomised, double-blind, placebo-controlled phase III multicentre study","volume":"56","author":"A Bohle","year":"2009","journal-title":"Eur Urol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1186\/s12894-020-00610-9","article-title":"Intravesical gemcitabine versus mitomycin for non-muscle invasive bladder cancer: a systematic review and meta-analysis of randomized controlled trial","volume":"20","author":"R Li","year":"2020","journal-title":"BMC Urol"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"e664","DOI":"10.1016\/j.juro.2011.02.1765","article-title":"Intravesical gemcitabine versus bacillus Calmette-Guerin (BCG) in treatment of non-muscle invasive bladder cancer: a short term comparative study","volume":"185","author":"L Bendary","year":"2011","journal-title":"J Urol"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1016\/j.eururo.2009.12.024","article-title":"Long-term efficacy results of EORTC genito-urinary group randomized phase 3 study 30911 comparing intravesical instillations of epirubicin, bacillus Calmette-Guerin, and bacillus Calmette-Guerin plus isoniazid in patients with intermediate- and high-risk stage Ta T1 urothelial carcinoma of the bladder","volume":"57","author":"RJ Sylvester","year":"2010","journal-title":"Eur Urol"},{"key":"ref11","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1159\/000273461","article-title":"Bacillus Calmette-Guerin versus gemcitabine for intravesical therapy in high-risk superficial bladder cancer: a randomised prospective study","volume":"84","author":"M Porena","year":"2010","journal-title":"Urol Int"},{"key":"ref12","doi-asserted-by":"publisher","first-page":"1893","DOI":"10.1002\/cncr.24914","article-title":"Gemcitabine versus bacille Calmette-Guerin after initial bacille Calmette-Guerin failure in non-muscle-invasive bladder cancer: a multicenter prospective randomized trial","volume":"116","author":"G Di Lorenzo","year":"2010","journal-title":"Cancer"},{"key":"ref13","doi-asserted-by":"publisher","first-page":"543","DOI":"10.1200\/JCO.2008.20.8199","article-title":"Randomized phase III trial on gemcitabine versus mytomicin in recurrent superficial bladder cancer: evaluation of efficacy and tolerance","volume":"28","author":"R Addeo","year":"2010","journal-title":"J Clin Oncol"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"620","DOI":"10.1016\/j.euf.2019.09.006","article-title":"Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer","volume":"6","author":"DC Grimberg","year":"2020","journal-title":"Eur Urol Focus"},{"key":"ref15","first-page":"4912","article-title":"Electromotive versus passive diffusion of mitomycin C into human bladder wall: concentration-depth profiles studies","volume":"59","author":"SM Di Stasi","year":"1999","journal-title":"Cancer Res"},{"key":"ref16","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/S1470-2045(05)70472-1","article-title":"Sequential BCG and electromotive mitomycin versus BCG alone for high-risk superficial bladder cancer: a randomised controlled trial","volume":"7","author":"SM Di Stasi","year":"2006","journal-title":"Lancet Oncol"},{"key":"ref17","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1097\/01.ju.0000080568.91703.18","article-title":"Intravesical electromotive mitomycin C versus passive transport mitomycin C for high risk superficial bladder cancer: a prospective randomized study","volume":"170","author":"SM Di Stasi","year":"2003","journal-title":"J Urol"},{"key":"ref18","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1016\/S1470-2045(11)70190-5","article-title":"Electromotive instillation of mitomycin immediately before transurethral resection for patients with primary urothelial non-muscle invasive bladder cancer: a randomised controlled trial","volume":"12","author":"SM Di Stasi","year":"2011","journal-title":"Lancet Oncol"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"62.e13","DOI":"10.1016\/j.urolonc.2021.07.019","article-title":"Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer","volume":"40","author":"OM Pijpers","year":"2021","journal-title":"Urol Oncol"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"3410","DOI":"10.1200\/JCO.2017.72.3064","article-title":"Intravesical rAd-IFNalpha\/Syn3 for Patients With High-Grade, Bacillus Calmette-Guerin-Refractory or Relapsed Non-Muscle-Invasive Bladder Cancer: A Phase II Randomized Study","volume":"35","author":"ND Shore","year":"2017","journal-title":"J Clin Oncol"},{"key":"ref21","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1016\/S1470-2045(20)30540-4","article-title":"Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial","volume":"22","author":"SA Boorjian","year":"2021","journal-title":"Lancet Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"1712","DOI":"10.1016\/j.juro.2012.07.020","article-title":"A phase II study of oportuzumab monatox: an immunotoxin therapy for patients with noninvasive urothelial carcinoma in situ previously treated with bacillus Calmette-Guerin","volume":"188","author":"M Kowalski","year":"2012","journal-title":"J Urol"},{"key":"ref23","doi-asserted-by":"publisher","first-page":"1912885","DOI":"10.1080\/2162402X.2021.1912885","article-title":"Safety, Tolerability, and Long-Term Clinical Outcomes of an IL-15 analogue (N-803) Admixed with Bacillus Calmette-Guerin (BCG) for the Treatment of Bladder Cancer","volume":"10","author":"CJ Rosser","year":"2021","journal-title":"Oncoimmunology"}],"container-title":["Aktuelle Urologie"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1677-0952.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,4]],"date-time":"2022-07-04T16:10:53Z","timestamp":1656951053000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1677-0952"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,16]]},"references-count":22,"journal-issue":{"issue":"02","published-online":{"date-parts":[[2022,3,28]]},"published-print":{"date-parts":[[2022,4]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1677-0952","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0001-7868","1438-8820"],"issn-type":[{"value":"0001-7868","type":"print"},{"value":"1438-8820","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,2,16]]}}}